Serum complement levels in bacteremia due to gram-negative organisms.

The effects of bacterial endotoxins on host mediation systems. A review. Am J Pathol (1978) 6.03

Complement and meningococcal infection. Br Med J (1976) 2.28

Mediation systems in bacterial lipopolysaccharide-induced hypotension and disseminated intravascular coagulation. I. The role of complement. J Exp Med (1975) 1.91

C1-inhibitor substitution therapy in septic shock and in the vascular leak syndrome induced by high doses of interleukin-2. Intensive Care Med (1993) 1.45

Anti-c5a ameliorates coagulation/fibrinolytic protein changes in a rat model of sepsis. Am J Pathol (2002) 1.33

Activation of complement by opportunist pathogens and chemotypes of Salmonella minnesota. Infect Immun (1977) 1.32

Hyperactivity of neutrophil leukotactic responses during active bacterial infection. J Clin Invest (1974) 1.29

Increased mean platelet volume in septicaemia. J Clin Pathol (1983) 1.26

K-1 antigen of Escherichia coli: epidemiology and serum sensitivity of pathogenic strains. Infect Immun (1978) 1.23

Proteolytic inactivation of plasma C1- inhibitor in sepsis. J Clin Invest (1989) 1.22

C5a-induced hemodynamic and hematologic changes in the rabbit. Role of cyclooxygenase products and polymorphonuclear leukocytes. Am J Pathol (1987) 1.18

The effect of complement depletion on bacterial lipopolysaccharide (LPS)-induced hemodynamic and hematologic changes in the Rhesus monkey. Am J Pathol (1978) 1.14

Clinical application of a new nephelometric technique to measure complement activation. J Clin Pathol (1983) 1.13

Effect of temperature on bacterial killing by serum and by polymorphonuclear leukocytes. Infect Immun (1977) 1.06

Circulating complement proteins in patients with sepsis or systemic inflammatory response syndrome. Clin Diagn Lab Immunol (1996) 1.01

Host defense against opportunist microorganisms following trauma. II. Changes in complement and immunoglobulins in patients with abdominal trauma and in septic patients without trauma. Ann Surg (1978) 0.97

Review: assessment of complement activation in clinical immunology laboratories: time for reappraisal? J Clin Pathol (1989) 0.95

Activation of the complement system in baboons challenged with live Escherichia coli: correlation with mortality and evidence for a biphasic activation pattern. Infect Immun (1993) 0.92

Alternative complement pathway activation increases mortality in a model of burn injury in mice. J Clin Invest (1982) 0.89

Brain damage complicating septic shock: acute haemorrhagic leucoencephalitis as a complication of the generalised Shwartzman reaction. J Neurol Neurosurg Psychiatry (1979) 0.87

Development and application of an enzyme-linked immunosorbent assay for the quantitation of alternative complement pathway activation in human serum. J Clin Invest (1984) 0.83

Preferential activation and depletion of the alternative complement pathway by burn injury. Ann Surg (1983) 0.81

Complement activation by whole endotoxin is blocked by a monoclonal antibody to factor B. Infect Immun (1994) 0.81

Experimental transmission of Neisseria gonorrhoeae from pregnant rat to fetus. Infect Immun (1999) 0.80

Toxicity of group B Streptococcus agalactiae in adult rats. Infect Immun (1985) 0.80

A new experimental polytrauma model in rats: molecular characterization of the early inflammatory response. Mediators Inflamm (2012) 0.80

A model for the interplay of inflammatory mediators in sepsis--a study in 48 patients. Intensive Care Med (1990) 0.75

Gram-negative bacteremia. III. Reassessment of etiology, epidemiology and ecology in 612 patients. Am J Med (1980) 4.45

Gram-negative bacteremia. IV. Re-evaluation of clinical features and treatment in 612 patients. Am J Med (1980) 3.03

Comparison of the antibacterial activity of rifampicin and other antibiotics. Am J Med Sci (1968) 3.03

Immunization with R mutants of S. Minnesota. I. Protection against challenge with heterologous gram-negative bacilli. J Immunol (1972) 2.89

Limitations of the usefulness of the Limulus assay for endotoxin. N Engl J Med (1973) 2.84

Escherichia coli in bacteremia: K and O antigens and serum sensitivity of strains from adults and neonates. J Infect Dis (1978) 2.72

Nosocomial pneumonia in intubated patients given sucralfate as compared with antacids or histamine type 2 blockers. The role of gastric colonization. N Engl J Med (1987) 2.64

Activation of the properdin pathway of complement in patients with gram-negative of bacteremia. N Engl J Med (1975) 2.63

Pseudobacteremia caused by povidone-iodine solution contaminated with Pseudomonas cepacia. N Engl J Med (1981) 2.56

Type-specific and cross-reactive antibodies in gram-negative bacteremia. N Engl J Med (1972) 2.42

Extrapulmonary tuberculosis revisited: a review of experience at Boston City and other hospitals. Medicine (Baltimore) (1984) 2.28

Bacterial infections in adult patients with the acquired immune deficiency syndrome (AIDS) and AIDS-related complex. Am J Med (1987) 2.04

Risk factors for pneumonia and fatality in patients receiving continuous mechanical ventilation. Am Rev Respir Dis (1986) 2.04

The relation of K-antigen to virulence of Escherichia coli. J Infect Dis (1975) 1.64

Nosocomial infection and fatality in medical and surgical intensive care unit patients. Arch Intern Med (1988) 1.58

Immunization with R mutants of Salmonella minnesota. II. Serological response to lipid A and the lipopolysaccharide of Re mutants. Infect Immun (1977) 1.56

Nephrotoxicity associated with cephalothin administration. Arch Intern Med (1975) 1.40

Immunization with R mutants of Salmonella minnesota. II. Comparison of the protective effect of immunization with lipid A and the Re mutant. Infect Immun (1977) 1.39

An outbreak of type 1 pneumococcal pneumonia in a men's shelter. JAMA (1980) 1.38

Bacteremia due to Fusobacterium species. Am J Med (1983) 1.35

Pseudobacteremia traced to cross-contamination by an automated blood culture analyzer. Infect Control (1984) 1.33

Mycobacterial cervical lymphadenopathy. Relation of etiologic agents to age. JAMA (1984) 1.31

Immunization with rough mutants of Salmonella minnesota. IV. Protection by antisera to O and rough antigens against endotoxin. J Infect Dis (1983) 1.29

Common enterobacterial antigen. I. Isolation and purification from Salmonella typhose 0:901. J Immunol (1973) 1.28

"Abacterial" and bacterial pyelonephritis. Immunofluorescent localization of bacterial antigen. N Engl J Med (1969) 1.28

A large outbreak of infections caused by a strain of Staphylococcus aureus resistant of oxacillin and aminoglycosides. Am J Med (1981) 1.28

Meningitis caused by gram-negative bacilli. Ann Intern Med (1980) 1.27

Vancomycin treatment of bacteremia caused by oxacillin-resistant Staphylococcus aureus: comparison with beta-lactam antibiotic treatment of bacteremia caused by oxacillin-sensitive Staphylococcus aureus. J Infect Dis (1983) 1.24

Effects of IgM and IgG antibody in patients with bacteremia due to gram-negative bacilli. J Infect Dis (1976) 1.24

M proteins of group G streptococci isolated from bacteremic human infections. Infect Immun (1987) 1.24

Selective pressures and lipopolysaccharide subunits as determinants of resistance of clinical isolates of gram-negative bacilli to human serum. Infect Immun (1987) 1.20

Contaminated medication nebulizers in mechanical ventilator circuits. Source of bacterial aerosols. Am J Med (1984) 1.14

Immunofluorescent demonstration of the common enterobacterial antigen. Proc Soc Exp Biol Med (1966) 1.12

Meningitis caused by Acinetobacter calcoaceticus var anitratus. A specific hazard in neurosurgical patients. Arch Neurol (1981) 1.11

Cross-reactive antigens: their potential for immunization-induced immunity to Gram-negative bacteria. J Infect Dis (1977) 1.07

Bacteremia due to Mycobacterium tuberculosis in patients with human immunodeficiency virus infection. A report of 9 cases and a review of the literature. Medicine (Baltimore) (1990) 1.05

Immunization with rough mutants of Salmonella minnesota: initial studies in human subjects. J Infect Dis (1988) 1.04

Gram-negative bacteremia. Adv Intern Med (1974) 1.00

Common enterobacterial antigen. 3. Initial titers and antibody response in bacteremia caused by gram-negative bacilli. Infect Immun (1973) 0.93

Immunofluorescent localization of bacterial antigen in pyelonephritis. I. The use of antisera against the common enterobacterial antigen in experimental renal lesions. J Lab Clin Med (1967) 0.93

Endotoxin and bacteremia due to gram-negative organisms. N Engl J Med (1970) 0.91

Bacteremia caused by group G streptococci in parenteral drug abusers: epidemiological and clinical aspects. J Infect Dis (1986) 0.90

Contamination of mechanical ventilators with tubing changes every 24 or 48 hours. N Engl J Med (1982) 0.89

Bacterial interference induced in embryonated eggs by staphylococci. J Clin Invest (1967) 0.88

Common enterobacterial antigen. II. Effect of immunization on challenge with heterologous bacilli. Infect Immun (1973) 0.87

Antibiotics and endotoxic shock. Bull N Y Acad Med (1975) 0.84

Methicillin-resistant Staphylococcus aureus bacteremia linked to intravenous drug abusers using a "shooting gallery". Am J Med (1986) 0.83

Naloxone versus placebo in treatment of septic shock. Lancet (1985) 0.83

A randomized study comparing a transparent polyurethane dressing to a dry gauze dressing for peripheral intravenous catheter sites. Infect Control (1985) 0.83

Clinical use of combinations of antimicrobial agents. Antimicrob Agents Chemother (Bethesda) (1967) 0.82

Interactions of rifampin and trimethoprim in vitro. Rev Infect Dis (1982) 0.81

Endotoxin-associated protein: a potent stimulus for human granulocytopoietic activity which may be accessory cell independent. Infect Immun (1988) 0.81

Endotoxin-associated protein: interleukin-1-like activity on serum amyloid A synthesis and T-lymphocyte activation. Infect Immun (1988) 0.80

Randomized clinical trial of aztreonam and aminoglycoside antibiotics in the treatment of serious infections caused by gram-negative bacilli. Antimicrob Agents Chemother (1989) 0.80

The role of lipopolysaccharide of gram-negative bacilli in sensitivity and resistance to serum. Prog Clin Biol Res (1988) 0.80

Pathophysiology of bacteremia. Am J Med (1983) 0.79

Xanthogranulomatous pyelonephritis caused by methicillin-resistant Staphylococcus aureus. Am J Med (1984) 0.79

Gram-negative bacteremia. Dis Mon (1973) 0.79

Potential use of shared antigens for immunization against gram-negative bacillary infections. Prog Clin Biol Res (1980) 0.78

Studies of staphylococcal infections. II. The role of bacteriophage type, antibiotic resistance, coagulase, and other exotoxins in infections in embryonated eggs. Yale J Biol Med (1966) 0.78

Empiric therapy for bacterial meningitis. Rev Infect Dis (1983) 0.77

Ototoxicity of erythromycin. Lancet (1978) 0.77

Antibody to endotoxin in the treatment of gram-negative sepsis. JAMA (1992) 0.77

Humoral immunity to gram-negative bacillary infections in experimental animals and man. Infection (1975) 0.76

Naloxone in septic shock. Lancet (1985) 0.75

A model for bacterial clearance in the lung. Surgery (1972) 0.75

In vitro studies of moxalactam (LY127935), a new beta-lactam antibiotic with significant activity against gram-negative bacteria. Infection (1980) 0.75

Immunoprophylaxis of gram-negative bacillary infections. Annu Rev Med (1976) 0.75

Role of the reticuloendothelial system in bacterial interference in embryonated eggs. J Lab Clin Med (1968) 0.75

Gram-negative rod bacteremia in cancer patients. A review with emphasis on the antibody response. Eur J Cancer (1975) 0.75

Letter: Incidence of gram-negative bacteremia. N Engl J Med (1975) 0.75

Trichinosis. Report of a small outbreak with observations of thiabendazole therapy. Arch Intern Med (1967) 0.75

University of California/Davis Interdepartmental Conference on gram-negative septicemia. Rev Infect Dis (1991) 0.75

Adult bacteremia caused by gram-negative bacilli. Clin Obstet Gynecol (1979) 0.75

The correlation of in vitro tests with the outcome of antimicrobial therapy for otitis media. Pediatr Ann (1984) 0.75

A clinical study of moxalactam in the treatment of infections due to gram-negative bacilli. Scand J Infect Dis (1984) 0.75

Detection of bacterial antigen in bacterial and "abacterial" pyelonephritis. Trans Assoc Am Physicians (1969) 0.75